News articles about Repros Therapeutics (NASDAQ:RPRX) have trended somewhat positive this week, according to Accern. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Repros Therapeutics earned a media sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 45.9896441808669 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the news articles that may have impacted Accern Sentiment’s scoring:

Separately, Laidlaw lowered shares of Repros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, July 21st.

Repros Therapeutics (RPRX) traded down 7.8228% during mid-day trading on Wednesday, hitting $0.4619. 797,349 shares of the stock traded hands. Repros Therapeutics has a 1-year low of $0.26 and a 1-year high of $2.15. The stock’s market cap is $17.37 million. The company’s 50 day moving average price is $0.43 and its 200-day moving average price is $0.50.

Repros Therapeutics (NASDAQ:RPRX) last posted its quarterly earnings data on Monday, August 14th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.14. Repros Therapeutics had a negative net margin of 56,062.07% and a negative return on equity of 412.64%. The company had revenue of $0.01 million for the quarter. Analysts predict that Repros Therapeutics will post ($1.07) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Repros Therapeutics (RPRX) Earns Daily Media Impact Score of 0.16” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/01/repros-therapeutics-rprx-earns-daily-media-impact-score-of-0-16.html.

Repros Therapeutics Company Profile

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.

Insider Buying and Selling by Quarter for Repros Therapeutics (NASDAQ:RPRX)

Receive News & Stock Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related stocks with our FREE daily email newsletter.